WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus

Key Takeaways WST is seeing strong growth from GLP-1-related high-value components and auto-injector demand. WST's Annex 1 projects are driving a favorable mix shift toward higher-margin pharma offerings. Margin pressure stems from WST's lower-margin product growth, pricing headwinds and $20-$25M in new tariffs.West Pharmaceutical Services, Inc. (WST) is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning ...